Use Able AI chat for product recommendations

Recombinant Human FGFR2(IIIc) protein (hFc Tag, Myc Tag, His Tag)(HPLC verified)

Species

Human

Purity

>95 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

hFc Tag, Myc Tag, His Tag

Activity

EC50: 75-300 ng/mL

Cat no : Eg0193



Product Information

Purity >95 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Human FGF basic (His tag) at 1 μg/mL (100 μL/well) can bind Human FGFR2 (IIIc) (hFc tag, Myc tag, His tag) with a linear range of 75-300 ng/mL.
Expression HEK293-derived Human FGFR2 (IIIc) protein Arg22-Glu377 (Accession# P21802-1) with a human IgG1 Fc tag, a Myc tag and a His tag at the C-terminus.
GeneID 2263
Accession P21802-1
PredictedSize 68 kDa
SDS-PAGE 85-100 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

FGFR2 (Fibroblast growth factor receptor 2) is a tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis. Ligand binding leads to the activation of several signaling pathway, such as RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP Kinase signaling pathway, as well as the AKT1 signaling pathway. Mutations in the gene of FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis.

References:

1.Eswarakumar VP, et al. (2005). Cytokine Growth Factor Rev. 16(2):139-149. 2.Pike, KG. (2017). Topics in Medicinal Chemistry. 8. 3.Azoury SC, et al. (2017). Int J Biol Sci. 13(12):1479-1488.

||
New chat

Able™

正在加载,请稍候...